GNPX NASDAQ
Genprex, Inc.
1W: -20.1%
1M: -25.1%
3M: -80.8%
YTD: -93.3%
1Y: -98.7%
3Y: -100.0%
5Y: -100.0%
$2.63
+0.07 (+2.73%)
Weekly Expected Move ±11.8%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3M
52W Range2.53-1210
Volume113,965
Avg Volume167,248
Beta-0.93
Dividend—
Analyst Ratings
Company Info
CEORyan Confer
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2018-03-29
Websitegenprex.com
3300 Bee Cave Road
Austin, TX 78746
US
Austin, TX 78746
US
877 774 4679
About Genprex, Inc.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
Top 3 Health Care Stocks That Are Set To Fly In Q2
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| LONGNECKER BRENT M | S-Sale | 8 | $1.23 | 2026-04-14 |
| LONGNECKER BRENT M | S-Sale | 10 | $1.23 | 2026-04-14 |
| Berger Mark Stanley | F-InKind | 7,168 | $2.00 | 2026-02-27 |
| Confer Ryan M. | F-InKind | 9,330 | $2.00 | 2026-02-27 |
| Moreno Toscano Jose | A-Award | 9,000 | — | 2025-12-22 |